Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799695 · ClinicalTrials.gov registry record · NA
Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 561
- Enrollment target
NCT00799695 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 561 participants.
The verdict
NCT00799695, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 561 participants
- Enrollment target
Study Summary
Diabetic retinopathy is the major cause of blindness in working age Americans, and screening for it is cost-effective. There are a quarter of a million people in Southeast Michigan with diabetes and pre-diabetes. Only half of patients with diabetes are screened regularly for diabetic retinopathy, and this proportion has been difficult to increase despite various interventions. Previous research focused on HMO patient groups because preventative care was thought to decrease plan costs. In addition, it was administratively feasible to track patient-doctor interactions. This project builds on published research and institutional experience to determine an effective method for increasing the screening rate, in a mobile, non-HMO population. It uses administrative methods and information technology infrastructures, such as large scale electronic medical records and patient demographic databases, to identify existing patients requiring examinations. Patients were telephoned by a trained service representative who offered and scheduled firm examination appointment times. Hypothesis: Annual screening rates for diabetic retinopathy can be substantially improved in non-HMO patient groups by directly contacting patients and scheduling firm appointment times.
Interventions
- BEHAVIORAL phone call contact
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 561 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799695
The ClinicalTrials.gov registry entry for NCT00799695 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 561 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which phone call contact is the first listed.
NCT00799695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00799695 about?
NCT00799695 is a clinical study titled "Diabetic Retina Exam Rate Does Not Increase With Phone Reminders in Non-HMO Population". Diabetic retinopathy is the major cause of blindness in working age Americans, and screening for it is cost-effective. There are a quarter of a million people in Southeast Michigan with diabetes and pre-diabetes. Only half of patients with diabetes are screened regularly for diabetic retinopathy, a...
What is the current status of trial NCT00799695?
This trial is currently completed. It is a NA study. The enrollment target is 561 participants. The study started on 2008-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00799695?
The interventions under investigation include: phone call contact (BEHAVIORAL).
Who is sponsoring clinical trial NCT00799695?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.